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Purpose: In vitro disintegration and dissolution are routine methods used to assess the performance and
quality of oral dosage forms. The purpose of the current work was to determine the potential for interaction
between capsule shell material and a green tea extract and the impact it can have on the release. 
Methods: A green tea extract was formulated into simple powder-in-capsule formulations of which the
capsule shell material was either of gelatin or HPMC origin. The disintegration times were determined
together with the dissolution proﬁles in compendial and biorelevant media. 
Results: All formulations disintegrated within 30 min, meeting the USP criteria for botanical formulations. An
immediate release dissolution proﬁle was achieved for gelatin capsules in all media but not for the speciﬁed
HPMC formulations. Dissolution release was especially impaired for HPMC gell at pH 1.2 and for both HPMC
formulations in FeSSIF media suggesting the potential for food interactions. 
Conclusions: The delayed release from studied HPMC capsule materials is likely attributed to an interaction
between the catechins, the major constituents of the green tea extract, and the capsule shell material. An
assessment of in vitro dissolution is recommended prior to the release of a dietary supplement or clinical
trial investigational product to ensure efﬁcacy. 
c © 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-SA license. 
 
 
 
 
 
 
 
 
 
 
 1. Introduction 
To date (assessed mid 2013) there are a total of 135 clinical trials
registered with clinicaltrials.gov in which a green tea extract (GTE)
has been used as an investigational product (search criteria: “green
tea extract”) and 44 of these trials appear under the search “green
tea extract capsules”. However, scarce public data exist on the qualityAbbreviations: BA, bioavailability; BCS, biopharmaceutical classiﬁcation system; C, 
catechin; DS, dietary supplement; EC, epicatechin; ECG, epicatechin gallate; EGCG, epi- 
gallocatechin gallate; EGC, epigallocatechin; FaSSIF, fasted state simulated intestinal 
ﬂuid; FeSSIF, fed state simulated intestinal ﬂuid; GA, gallic acid; GTE, green tea extract; 
HPMC, hydroxypropyl methylcellulose; HPMC carr , hydroxypropyl methylcellulose con- 
taining carrageenan; HPMC gell , hydroxypropyl methylcellulose containing gellan gum; 
IR, immediate release; PIC, powder-in-capsule; SIF, simulated intestinal ﬂuid; USP, 
United States Pharmacopeia. 
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Open access under CC BY-NC-SA licof these formulations with regard to meeting in vitro disintegration
and dissolution criteria and hence potential in vivo performance. The
two aforementioned methods are common measures of product per-
formance. There is increasing evidence that green and black tea con-
sumption has beneﬁcial health effects; such as reducing the risk for
cardiovascular diseases [ 1 ], supporting weight loss [ 2 ] and preventing
certain types of cancer [ 3 ]. These beneﬁts have led to the inclusion
and marketing of tea extracts in the form of dietary supplements (DS)
and functional foods. The beneﬁcial effects, e.g. anti-inﬂammatory,
anti-oxidative, are most likely associated with the high abundance of
bioactive molecules present in green and black tea, such as polyphe-
nols and more speciﬁcally the catechins [ 1 , 4 ]. Though numerous DS
containing GTE are commercially available, data on their actual in vitro
and in vivo performance and hence efﬁcacy are scarce. This is partly
attributed to the fact that DS are not required by regulatory bodies
to undergo the same stringent testing procedures as pharmaceuti-
cal formulations before they can be marketed. Therefore, unless the
manufacturer makes a label claim, supplements can be marketed on
the basis of safety data only. However, the same factors affecting the
bioavailability (BA) and efﬁcacy of drugs also apply to DS and hence
proper formulation design and testing is a crucial step in the devel-
opment of an efﬁcacious and safe DS. The desired effect and hence
dissolution proﬁle will determine the formulation requirements e.g.
immediate release (IR) if an acute beneﬁt is desired vs. controlledense.
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Table 1 
Composition of the green tea extract as determined by HPLC. GA = gallic acid, EGC = 
epigallocatechin, C = catechin, EC = epicatechin, EGCG = epigallocatechin gallate, GCG 
= gallocatechin gallate, ECG = epicatechin gallate. 
Component mg / g Green tea extract 
GA 1.5 
EGC 2.5 
C 7.8 
Caffeine 8.1 
EC 59.8 
EGCG 523.9 
GCG 15.8 
ECG 164.9 
Total catechins 784.3 elease for long-term or delayed effects etc. [ 5 ]. This paper will fo- 
us on GTE powder-in-capsule (PIC) formulations intended for IR (the 
elease of the active is not deliberately modiﬁed by a special manu- 
acturing method or formulation design e.g. no addition of functional 
xcipients). 
Proper formulation of herbal / botanical extracts into an oral dosage 
orm is not only critical for producing a high quality market-ready 
roduct, but also in the “research and development phases” of new 
unctional food products. The preferred way to explore the efﬁcacy 
f lead ingredient(s) is via proof-of-principle clinical intervention 
tudies. In these early stages, clinical trials commonly employ sim- 
le standardized oral formulations of the active ingredients, such as 
ard-shell ﬁlled capsules. Hence, the quality and performance of such 
 test formulation will greatly impact the outcome of the clinical in- 
estigations and the results of these human interventions are pivotal 
n building a claims dossier for functional food ingredients. The out- 
ome of human intervention studies also helps determine whether a 
ead ingredient will be further developed or discontinued. As men- 
ioned earlier, PIC formulations are often the preferred choice due to 
heir ease of formulation, the assumed reduced implications regarding 
tability and BA of the active ingredient(s) and volunteer / consumer 
ompliance. Until recently gelatin has been the preferred material 
or capsule shells due to its gel forming characteristics and its ex- 
ellent solubility in biological ﬂuids [ 6 ], but more recently capsules 
ade from hydroxypropyl methylcellulose (HPMC) have been intro- 
uced as an attractive vegetarian alternative. Various kinds of HPMC 
apsules are currently available on the market, differing mainly in 
hether or not a gelling agent such as carrageenan or gellan gum 
s added to enhance the gelation process [ 6 ]. While HPMC is known 
o impact the dissolution, e.g. it serves as a matrix for use in ex- 
ended release tablet formulations, the potential interaction of HPMC 
s a capsule shell material with a botanical ﬁlling material such as 
olyphenols and characterization of the subsequent dissolution of 
uch formulations has not been explained in the literature. 
Even though catechins are readily soluble in the gastrointestinal 
uids, their limited absorption, rapid and variable metabolism and 
ctive efﬂux from the enterocytes impair their BA and efﬁcacy [ 7 , 8 ]. 
dditionally, the BA is complicated by the presence of food which 
an enhance or impair the absorption of the individual catechins [ 9 ]. 
ence, it is critical that formulation errors do not further contribute 
o limitations in BA of the active(s), as the rate and extent of release 
rom the dosage form is critical to achieve the desired beneﬁts. Since 
olyphenols are known to potentially interact with certain compound 
lasses such as proteins or cellulose derivatives [ 10 ], it is of great inter-
st to investigate the release properties of catechins when formulated 
nto different hard shell capsules such as gelatin or HPMC. 
. Objective 
The aim of this work was to design and test three simple PIC GTE 
ormulations, typical for use as a DS or clinical trial investigational 
roduct. As it is often assumed that there is no impact / limitation 
n the dissolution of the capsule contents of such formulations, IR 
issolution criteria were applied. The disintegration and dissolution 
roﬁles of a commercially available GTE formulated into various cap- 
ules of gelatin or HPMC origin were tested in both compendial and 
iorelevant media to determine the potential for food interactions. 
he intent of the results presented here is to address issues of formu- 
ation and the potential for interaction between GTE ingredients and 
apsule shell materials. 3. Material and Methods 
3.1. Materials 
Hydrochloric acid (37%), glacial acetic acid (100%) and acetonitrile 
were obtained from VWR (Briare, France). Mono-potassium phos- 
phate and sodium hydroxide were purchased from Sigma-Aldrich 
(Steinheim, Germany) and sodium acetate trihydrate was obtained 
from Riedel-de Ha ¨en (Seelze, Germany). Simulated intestinal ﬂuid 148 
(SIF) powder was purchased from Phares AG (Muttenz, Switzerland). 
Sunphenon 90 DCF-T (Lot 003191) was kindly donated by Taiyo Eu- 
rope (Fiderstadt, Germany); the composition of the extract is shown in 
Table 1 . Gelatin capsules, HPMC gell (“Vcaps”: HPMC; with gellan gum 
as gelling agent) and HPMC (“Vcaps Plus”: pure HPMC; no gelling 
agent), were obtained from Capsugel (Bornem, Belgium). 
3.2. Formulations 
The three different formulations tested in this study were (a) 
formulation “Gelatin”: 260 mg Sunphenon 90DCF-T in gelatin cap- 
sules, (b) formulation “HPMC gell ”: 260 mg Sunphenon-90DCF-T in 
HPMC capsules with gellan gum as the gelling agent and (c) for- 
mulation “HPMC”: 260 mg Sunphenon-90DCF-T in HPMC capsules 
without gelling agent. All capsules were size 0 and transparent. The 
formulations were prepared manually using a capsule ﬁlling machine 
(Capsunorm 2000, Tecnyfarma, Barcelona, Spain). 
3.3. Composition of compendial and biorelevant media 
The compendial media – 0.1 mol / l hydrochloric acid (pH 1.2), ac- 
etate buffer (pH 4.5) and phosphate buffer (pH 6.8) – were prepared 
according to USP 32. Fasted state simulated intestinal ﬂuid (FaSSIF) 
and fed state simulated intestinal ﬂuid (FeSSIF) were prepared from 
simulated intestinal ﬂuid (SIF) powder (Biorelevant.com, Croydon, 
Surrey, UK) [ 11 ]. 
3.4. Disintegration testing 
Capsule disintegration was tested according to USP 32 chapter 
< 2040 > with a disintegration tester ZT120 and tube / rack assem- 
bly Apparatus B (Erweka GmbH, Heusenstamm, Germany). Chapter 
< 2040 > also discusses the acceptance criteria for dietary supple- 
ments. The test for hard shell capsules was applied and as the USP 
advises to omit the use of discs for botanical dosage forms; capsules 
were placed in a metal spiral capsule sinker (ProSense BV Dissolution 
Accessories, Oosterhout, the Netherlands) to prevent ﬂoating which 
is a slight modiﬁcation of the description in < 2040 > . This modiﬁca- 
tion avoids the mechanical impact discs during each stroke and at the 
same time keeps the capsules submerged to ensure ample ﬂuid con- 
tact. The recorded capsule disintegration time is the time at which the 
capsule was visually observed to be completely disintegrated, even 
Natalie Glube et al. / Results in Pharma Sciences 3 (2013) 1–6 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Disintegration test: HPMC gell and HPMC capsules ﬁlled with green tea extract, 
in acetate buffer after 30 min, (A) HPMC gell and (B) HPMC 
Fig. 2. Capsule disintegration times for gelatin, HPMC gell and HPMC capsules ﬁlled with 
green tea extract in acetate buffer (pH 4.5) and de-mineralized water. Bars represent 
SD, n = 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 if some pieces of the capsule shell remained on the mesh of the test
basket. Disintegration of the formulations was assessed in two im-
mersion ﬂuids: the USP recommended 0.05 mol / l acetate buffer as
well as in demineralised water, both preheated to 37 ◦C. All experi-
ments were performed as n = 6 and the mean and standard deviation
were calculated. 
3.5. Dissolution testing 
A calibrated dissolution tester “VK 1700” (Varian Inc., Cary NC,
USA) was used for all dissolution studies. The formulations were
tested using the paddle method plus sinker (USP Apparatus 2), em-
ploying 900 ml of dissolution medium equilibrated to 37 ± 0.5 ◦C
and a rotational speed of 75 rpm. Spiral capsule sinkers (ProSense BV
Dissolution Accessories, Oosterhout, the Netherlands) were used to
prevent capsules from ﬂoating. Samples were taken after 5, 10, 20, 30,
45, 60 and 120 min by withdrawal of 2 ml at each sampling point and
the volume withdrawn was replaced with fresh pre-warmed medium.
Each sample was immediately ﬁltered through a 0.2 μm PVDF ﬁlter
(Type Acrodisc LC, Pall Life Sciences, Uithoorn, The Netherlands) and
directly analyzed by HPLC and / or appropriately diluted with buffer
media prior to UV–vis spectrophotometer analysis. Dissolution of
all three formulations was assessed using compendial media at pH
1.2 (0.1 mol / l HCl), pH 4.5 (acetate buffer) and pH 6.8 (phosphate
buffer) and the experiments were performed as n = 6. HPMC gell and
HPMC formulations were additionally tested in FaSSIF and FeSSIF ( n
= 3) due to the limitations observed in compendial media. Based on
FDA guidelines, a formulation was considered to meet IR criteria if no
less than 85% of the capsule content was released after 30 min [ 12 ]. 
3.6. Sample analysis 
For the experiments performed at pH 1.2 and 4.5, the concen-
tration of GTE released was recorded spectrophotometrically at the
maximum absorbance wavelength of 274 nm on a UV–vis spectro-
photometer “UV 1601” (Shimadzu, Duisburg, Germany). In both buffer
solutions the maximal phenolic absorption (representative of all phe-
nols present in the extract) was determined to be at 274 nm, hence
absorption values of samples at that wavelength were used to cal-
culate the percentage of active released. All standard curves were
prepared in the respective buffers and analyzed at the same wave-
length. 
3.7. HPLC analyses 
To conﬁrm the results obtained by the UV–vis spectrophotomet-
ric analysis, one of the six dissolution replicates was further ana-
lyzed by HPLC employing the same method as earlier described by
Wang et al. [ 13 ]. All HPLC analyses were carried out with a Shimadzu
class LC VP HPLC system with LC-Solution software (Shimadzu Cor-
poration, Kyoto, Japan). A dissolution proﬁle was generated for six
individual catechins present in the GTE: gallic acid (GA, PubChem
CID: 370), epicatechin (EC, PubChem CID: 72276), epigallocatechin
gallate (EGCG, PubChem CID: 65064), epicatechin gallate (ECG, Pub-
Chem CID: 107905), catechin (C, PubChem CID: 9064) and epigal-
locatechin (EGC, PubChem CID: 107905), as well as for the sum of
all catechins and compared to the dissolution proﬁle from the UV-
spectrophotometer analysis. The results from both analyses were in
excellent agreement with a mean deviation of 4.2 ± 4.8%. Hence,
UV-analysis was considered appropriate for all further analyses with
regard to pH 1.2 and 4.5. Due to sample instability in phosphate buffer
(pH 6.8), FaSSIF and FeSSIF media, samples from those experiments
were analyzed by HPLC and the dissolution proﬁle was generated
using EC as marker compound, since EC remained intact during the
entire time of the analysis (stability data not shown). 4. Results 
4.1. Disintegration 
In both media employed – acetate buffer (pH 4.5) as well as de-
mineralized water – the three formulations investigated released
their content within 30 min, meeting the USP criteria for disintegra-
tion of DS. The gelatin capsules optimally disintegrated as nothing
remained in the sinker or on the mesh of the basket rack assembly at
the end of the test. The capsule content was also released from the
two HPMC formulations, however, part of the capsule shell remained
on the mesh (HPMC gell ) and / or within the sinker (HPMC) after 30 min
and the mean disintegration time was considerably higher compared
to the gelatin capsules, see Figs. 1 and 2 . 
4.2. Dissolution 
The amounts of GTE dissolved over time in the ﬁve media em-
ployed are summarized in Table 1 . 
Dissolution at pH 1.2: The gelatin formulation disintegrated and
dissolved rapidly, achieving complete dissolution of the active within
10 min, see Fig. 3 . No residues of the capsule shell remained in the
sinker at the end of the experiment after 2 h. Both HPMC formula-
tions showed incomplete dissolution proﬁles. The release from the
HPMC formulation was hampered and only reached a maximum re-
lease of 69% after 2 h. The HPMC gell formulation was more signiﬁ-
cantly delayed with content release beginning after 1 h and reaching
a maximum release of 35% after 2 h. 
Dissolution pH 4.5: Similar to pH 1.2, fast and complete dissolu-
tion was achieved for the gelatin formulation. As shown in Fig. 4 ,
HPMC and HPMC gell showed a delayed release of the active and after
30 min dissolution values were 32% and 18%, respectively. At the end
of the experiments with the gelatin formulation, some gluey gelatin
residues adhered to the sinkers and for both HPMC formulations in-
tact parts of the capsule shell were associated in the sinker. 
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Fig. 3. Dissolution proﬁles showing the mean percentage of green tea extract (GTE) 
released from gelatin, HPMC gell and HPMC capsules in 0.1 M HCl buffer at pH 1.2, 37 
◦C, 75 rpm, 2 h. Bars represent SD, n = 6. 
Fig. 4. Dissolution proﬁles showing the mean percentage of green tea extract (GTE) 
released from 437 gelatin, HPMC gell and HPMC capsules in acetate buffer at pH 4.5, 37 
◦C, 75 rpm, 2 h. Bars represent 438 SD, n = 6. 
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Fig. 5. Dissolution proﬁles showing the mean percentage of green tea extract (GTE) 
released from gelatin, HPMC gell and HPMC capsules in phosphate buffer at pH 6.8, 37 
◦C, 75 rpm, 2 h. Bars represent SD, n = 6. 
Fig. 6. Dissolution proﬁles showing the mean percentage of green tea extract (GTE) 
released from HPMC gell and HPMC capsules in FaSSIF, pH 6.5, 37 
◦C, 75 rpm, 2 h. Bars 
represent SD, n = 3. 
Fig. 7. Dissolution proﬁles showing the mean percentage of green tea extract (GTE) 
released from HPMC gell and HPMC capsules in FeSSIF, pH 5, 37 
◦C, 75 rpm, 2 h. Bars 
represent SD, n = 3. Dissolution pH 6.8: Dissolution behaviour at pH 6.8 was similar to 
H 4.5. After an initial lag time of approximately 5 min, the gelatin 
apsules dissolved fast and complete dissolution was achieved within 
0 min. Both HMPC formulations showed again delayed release, after 
0 min only 7% and 15% were dissolved from the HPMC gell and HPMC 
ormulations, respectively (see Fig. 5 ). 
Dissolution in FeSSIF and FaSSIF: As shown in Figs. 6 and 7 , dissolu- 
ion in simulated intestinal ﬂuid (fed and fasted) did not improve the 
elease proﬁle of the HPMC formulations compared to the compen- 
ial media. In FaSSIF, 6% and 15% of the content was released after 
0 min and the maximal amount dissolved after 2 h were 33% and 
1% for HPMC gell and HPMC, respectively. Dissolution in FeSSIF was 
urther delayed with a content release after 30 min of 6% and 8%, and 
aximum release after 2 h of 64% and 54% for HPMC gell and HPMC, 
espectively. 
. Discussion 
The results of this study address a number of known concerns with 
egard to the quality and performance of marketed DS but is also in- 
ended to increase the awareness that similar issues must be dealt 
ith in regard to clinical trial test products. A key factor dictating 
he efﬁcacy of a DS or investigational product containing an active ingredient is the fraction of the ingested amount that is absorbed and 
reaches the target site, in a deﬁned period of time. The design of a 
Natalie Glube et al. / Results in Pharma Sciences 3 (2013) 1–6 5 
Table 2 
Dissolution of green tea extract from gelatin, HPMC gell and HPMC capsules at pH 1.2, 4.5, 6.8, FaSSIF and FeSSIF; dissolution conditions: 37 
◦C, 75 rpm, sampling time points 
from 5 to 120 min (average % dissolved ± SD, n = 6). 
Min Gelatin HPMC gell HPMC 
pH 1.2 pH 4.5 pH 6.8 pH 1.2 pH 4.5 pH 6.8 FaSSIF FeSSIF pH 1.2 pH 4.5 pH 6.8 FaSSIF FeSSIF 
5 39 ± 7 2 ± 2 1 ± 1 0 0 0 0 0 0 0 0 0 0 
10 91 ± 3 32 ± 16 14 ± 4 0 1 0 0 0 1 0 0 0 0 
20 94 ± 7 85 ± 4 83 ± 14 0 7 ± 10 3 ± 2 0 0 10 ± 7 10 ± 11 46 22 1 ± 1 
30 95 ± 6 90 ± 2 96 ± 11 0 18 ± 14 7 ± 6 6 ± 4 2 ± 2 18 ± 11 32 ± 18 15 ± 15 15 ± 8 8 ± 4 
45 95 ± 3 92 ± 2 96 ± 12 0 25 ± 17 13 ± 7 12 ± 13 4 ± 6 30 ± 19 47 ± 21 25 ± 12 41 ± 12 16 ± 9 
60 95 ± 5 92 ± 2 99 ± 10 2 ± 1 41 ± 22 17 ± 8 22 ± 23 12 ± 12 49 ± 20 59 ± 11 38 ± 11 54 ± 13 27 ± 18 
120 95 ± 4 94 ± 3 101 ± 9 35 ± 13 58 ± 11 25 ± 10 33 ± 29 64 ± 10 69 ± 17 80 ± 10 52 ± 11 61 ± 12 54 ± 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 formulation can greatly inﬂuence the in vitro and in vivo performance
and hence the efﬁcacy / safety of oral dosage forms. Any DS or inves-
tigational product that does not disintegrate and dissolve sufﬁciently
(in an appropriate time frame) before reaching the proximal intes-
tine will not present the active ingredient for intestinal uptake, hence
limiting absorption. 
This study aimed at understanding the impact of the capsule shell
material on the dissolution proﬁle of three simple PIC GTE formu-
lations intended for IR, such as they could be used as a DS or in a
clinical trial / nutrition intervention study where an immediate effect
was desired. In the tested formulations, the interference of any excip-
ient was eliminated and purely the interaction between the capsule
shell material and the active was investigated. The authors are aware
that excipients could alter the interactions and subsequent work is
underway to systematically investigate this further. Thus far, there
are a few studies published looking at the in vitro rupture time of
HPMC capsules, however most of the methods used were different
from the USP guidelines applied in our experiments or focus on other
active ingredients; e.g. Chiwele et al. [ 14 ] employed a ball bearing
method, El-Malal and Nazzal [ 15 ] and Ku et al. [ 16 ] used the USP ap-
paratus II with real time dissolution spectroscopy and Vardakou et al.
[ 17 ] estimated capsule rupture time with a USP apparatus I as well as
with a novel in vitro dynamic gastric model. From those experiments, a
trend for increased rupture time in the following order was observed:
Gelatin capsules < HPMC carr < HPMC < HPMC gell . Similar trends were
found in various in vivo scintigraphic measurements to estimate cap-
sule rupture time as well as in in vitro dissolution studies. Ku et al.
showed that HPMC is favourable over HPMC carr (HPMC capsules con-
taining carrageenan as a gelling agent) with respect to rupture time
at low pH but in vitro dissolution proﬁles with a range of compounds
at higher pH were similar [ 17 ]. The differences in rupture time be-
tween the capsules with and without gelling agent are however small
( ∼3 min) in relation to the time of a dissolution test (60 min). The ob-
servations from Ku et al. are subject of scientiﬁc debate with respect
to their correct interpretation and meaning [ 18 ]. Cole et al. reported
delayed dissolution of HPMC gell especially in acidic media and phos-
phate buffer when compared to gelatin [ 19 ]. Additionally, the in vivo
data showed slower disintegration of HPMC gell compared to gelatin
capsules in both, fasted and fed states. However, very similar in vivo
disintegration times in fasted state for HPMC carr and gelatin capsules
was reported by Tuleu et al. [ 20 ]. 
The disintegration test is routinely used as a performance test for
immediate release oral dosage forms. The data from our disintegra-
tion experiments align nicely with the aforementioned trends from
the literature; regardless of the immersion ﬂuid used, the gelatin for-
mulations disintegrated approximately twice as fast as both HPMC
formulations; nevertheless, all formulations passed the USP require-
ments of the disintegration test for botanical dosage forms. However,
while for the gelatin capsules the content release appeared to be
due to a uniform disintegration and dissolution of the capsule shell
and subsequent liberation of the active, the content release from the
HPMC capsules appeared to be caused by ruptures at the weakestpoints of the capsule shell without full disintegration of the shell it-
self; large portions of the shell remained on the mesh or inside the
sinker after the 30 min test interval. Donauer and L ¨obenberg sug-
gested that acetate buffer might not be a suitable media for in vitro
disintegration testing of HPMC capsules since the presence of cations
may hinder fast dissolution of the shell and the use of de-mineralized
water would therefore be more appropriate [ 21 ]. However, our results
showed similar disintegration times for HPMC capsules in both me-
dia, indicating that the current USP recommendation to use acetate
buffer for disintegration testing of botanical dosage forms is adequate
in this scenario. 
Similar trends in the performance of the three formulations were
observed in the dissolution experiments. As expected, the gelatin
capsules disintegrated and dissolved rapidly, and achieved over 85%
release after 30 min in all three compendial media, 0.1 mol / L HCl (pH
1.2), acetate buffer (pH 4.5) and phosphate buffer (pH 6.8). Capsule
opening and content liberation were slower for the two HPMC for-
mulations, both showing rather a proﬁle of a delayed release than an
IR formulation. In particular, the HPMC gell at pH 1.2 showed a very
poor performance as content release was ﬁrst detectable after 60 min
and reached a maximum of 35% release within 2 h; this slow release
was also conﬁrmed visually with an example photograph taken af-
ter 30 min ( Fig. 1 ). It appears as if media penetrated the capsule and
wetting of the content occurred but the capsule shell remained in-
tact, thereby trapping the contents and preventing complete release
and subsequent dissolution. These ﬁndings are in line with a previ-
ous study where a slow in vitro and in vivo disintegration of HPMC gell
in acidic environment was reported [ 19 ]. The delayed dissolution of
those capsules was generally attributed to the ionic interactions be-
tween gellan gum in the HPMC gell and the acidic buffer, resulting in a
lower solubility of gellan gels at low pH. The dissolution proﬁle of the
HPMC gell improved slightly at pH 4.5, pH 6.8, FaSSIF and FeSSIF, how-
ever, the dissolution proﬁle deviated substantially to that what would
be required of an IR formulation. The HPMC formulation performed
slightly better than the HPMC gell , but still exhibited a delayed release
of the content and did not meet IR criteria. This is contradictory to
what could be expected as in previous studies, HPMC capsules either
ﬁlled with a BCS class 1, 2 or 4 compound or a mixture of caffeine,
lactose and croscarmellose were shown to dissolve rapidly at pH 1.2
and 4.5 [ 22 ]. The delayed release in our experiments can potentially
be attributed to an interaction between the GTE and HPMC wall ma-
terial immediately after the ﬁrst signs of rupture and wetting of the
GTE while inside the still largely intact capsule. As seen in the com-
position of the GTE ( Table 1 ), the main constituents are the catechins
EGCG (67%) and EGC (21%). Polyphenols and catechins in particular,
have been shown to interact with proteins such as gelatin / collagen
[ 23 , 24 ] but also with cellulose derivatives such as HPMC [ 25 ], result-
ing in insoluble complexes. Further experiments would be required
to identify the speciﬁc catechin or potentially other compound(s) of
the GTE causing the interaction. As mentioned earlier, the addition
of a dispersant might reduce this interaction and hence improve the
dissolution of the formulation. This could be especially useful for DS,
6 Natalie Glube et al. / Results in Pharma Sciences 3 (2013) 1–6 
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Rowever, formulations used for clinical intervention trials are often 
ept as simple as possible to eliminate any potential physiological 
ffect thereof, but as shown in this study this may limit complete 
elease. 
Table 2 
The dissolution in biorelevant media showed a delayed onset and 
ate of dissolution in the simulated fed state compared to the simu- 
ated fasted state. These results were in good agreement with previ- 
usly reported in vitro and in vivo studies [ 16 , 19 ]. The trend towards 
onger rupture times in the simulated fed state may be attributed to 
he slower hydration and softening rate of the tested capsule shell 
aterials in the presence of food. Whether this would also hold for 
ther HPMC capsule types and gelling agents is still unclear. Data 
rom dissolution in FaSSIF and FeSSIF are especially valuable to plan 
he time of administration, e.g. whether to dose with or without a 
eal. 
. Conclusion 
In conclusion, in order to properly design and guide nutrition in- 
ervention trials and to enhance the success rate of an investigational 
roduct or DS, a good understanding of the formulation’s in vitro per- 
ormance is crucial, as the release proﬁles will greatly affect the tim- 
ngs of clinical measurements. No- or negative-effect trials are often 
ttributed to the active ingredient itself, rather than the formulation. 
nsufﬁcient information on the quality and performance of the in- 
estigational product can lead to false negative and / or false-neutral 
nterpretations of clinical data. GTE speciﬁcally, indicated variable 
isintegration and dissolution proﬁles depending on the capsule shell 
aterial employed. Therefore, it is recommended the performance of 
olid oral dosage forms intended for use as a DS or clinical trial inves- 
igational product be veriﬁed preferably with an in vitro dissolution 
est prior to the product being released. 
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